We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Routine Helicobacter pylori Screening Post-Myocardial Infarction: Insights from the HELP-MI SWEDEHEART Trial

MedXY Editorial Team•Oct 6, 2025•Cardiology
Helicobacter pylorimyocardial infarctionscreening

Highlight

– Routine Helicobacter pylori (H. pylori) screening during hospitalization for myocardial infarction (MI) did not significantly lower upper gastrointestinal bleeding (UGIB) incidence.
– About 70% of patients were screened, with a 23.6% infection positivity rate.
– Subgroup analyses suggest potential benefit of screening in patients with anemia or kidney failure.
– Current evidence does not support universal H. pylori screening after MI, but targeted approaches may be warranted.

Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Targeting the CCND1-PDK4 Axis to Promote Reparative Macrophage Phenotype and Mitigate Post-Myocardial Infarction Cardiac RemodelingThis article discusses the role of cyclin D1 (CCND1) in promoting reparative macrophage transition post-myocardial infarction, highlighting its therapeutic potential in reducing adverse cardiac remodeling through metabolic reprogramming.Sep 19, 2026Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D TrialThe TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary comSep 17, 2026Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World PracticeThis randomized trial evaluates the safety and efficiency of the ESC 0/1-hour versus 0/3-hour high-sensitivity troponin pathways in suspected acute coronary syndrome, showing noninferior safety but no significant improvement in rapid dischaSep 17, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
New International Consensus: Colorectal Cancer Risk in MASLD — What Clinicians Need to Know
An international Delphi panel concludes metabolic dysfunction‑associated steatotic liver disease (MASLD) raises colorectal cancer (CRC) risk. Experts call for earlier, risk‑adapted CRC screening and integrated metabolic care to reduce CRC b
Sep 15, 2026
New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 DiabetesAn international expert consensus recommends practical principles and minimum requirements for general‑population screening for islet autoantibodies to detect early-stage type 1 diabetes, reduce DKA, enable early care and access to disease‑Sep 13, 2026
Stent Retriever Thrombectomy Reduces Infarct Size in High-Thrombus Myocardial Infarction: Insights from the NATURE TrialThe NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.Sep 6, 2026